10x GenomicsTXG
About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Employees: 1,259
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
209% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $2.06M
39% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 72
9% more capital invested
Capital invested by funds: $2.16B [Q2] → $2.35B (+$193M) [Q3]
1% more funds holding
Funds holding: 257 [Q2] → 260 (+3) [Q3]
6% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 54
7.17% less ownership
Funds ownership: 105.19% [Q2] → 98.02% (-7.17%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Barclays Luke Sergott 26% 1-year accuracy 12 / 46 met price target | 44%upside $19 | Overweight Maintained | 1 Nov 2024 |
Citigroup Patrick Donnelly 33% 1-year accuracy 9 / 27 met price target | 75%upside $23 | Buy Maintained | 30 Oct 2024 |
Goldman Sachs Matthew Sykes 60% 1-year accuracy 27 / 45 met price target | 6%upside $14 | Sell Maintained | 30 Oct 2024 |
JP Morgan Rachel Vatnsdal 48% 1-year accuracy 10 / 21 met price target | 6%upside $14 | Neutral Maintained | 30 Oct 2024 |
UBS Dan Leonard 56% 1-year accuracy 5 / 9 met price target | 52%upside $20 | Neutral Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 12 articles about TXG published over the past 30 days
